Inactivation of the macrolide antibiotics erythromycin, midecamycin, and rokitamycin by pathogenic Nocardia species
暂无分享,去创建一个
S. Iwasaki | N. Morisaki | Y. Ueno | K. Yazawa | Y. Mikami | K. Furihata | T. Sakamoto | Tomoko Sakamoto | '. Y. Ueno | Shigeo Iwasaki | Kazuo | Furihata
[1] S. Iwasaki,et al. Inactivated products of rifampicin by pathogenic Nocardia spp.: structures of glycosylated and phosphorylated metabolites of rifampicin and 3-formylrifamycin SV. , 1993, The Journal of antibiotics.
[2] P. Doherty,et al. Microbial conversion of avermectins by Saccharopolyspora erythraea: glycosylation at C-4' and C-4'' , 1993, Antimicrobial Agents and Chemotherapy.
[3] S. Iwasaki,et al. Inactivation of rifampin by Nocardia brasiliensis , 1993, Antimicrobial Agents and Chemotherapy.
[4] M. Miyaji,et al. In-vitro activity of new carbapenem antibiotics: comparative studies with meropenem, L-627 and imipenem against pathogenic Nocardia spp. , 1992, The Journal of antimicrobial chemotherapy.
[5] E. Cundliffe,et al. Cloning and characterization of two genes from Streptomyces lividans that confer inducible resistance to lincomycin and macrolide antibiotics. , 1991, Gene.
[6] R. Leclercq,et al. Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria , 1991, Antimicrobial Agents and Chemotherapy.
[7] T. Kudo,et al. Inactivation of Kanamycin A by Phosphorylation in Pathogenic Nocardia , 1991, Microbiology and immunology.
[8] E. Eady,et al. Multiple mechanisms of erythromycin resistance. , 1990, The Journal of antimicrobial chemotherapy.
[9] M. Kuo,et al. Microbial glycosylation of erythromycin A , 1989, Antimicrobial Agents and Chemotherapy.
[10] K. Yazawa,et al. In vitro susceptibility of Nocardia spp. to a new fluoroquinolone, tosufloxacin (T-3262) , 1989, Antimicrobial Agents and Chemotherapy.
[11] K O'Hara,et al. Purification and characterization of macrolide 2'-phosphotransferase from a strain of Escherichia coli that is highly resistant to erythromycin , 1989, Antimicrobial Agents and Chemotherapy.
[12] R. A. Johnson,et al. Microbial O-phosphorylation of macrolide antibiotics. , 1989, The Journal of antibiotics.
[13] H. Seto,et al. Particular utility of the HMBC technique to polypropionate derived metabolites as exemplified by erythromycin A. , 1988, The Journal of antibiotics.
[14] J. Cialdella,et al. Enzymatic phosphorylation of macrolide antibiotics. , 1987, The Journal of antibiotics.
[15] S. Inouye,et al. Studies on antibiotic SF-837, a new antibiotic. IV. Structures of antibiotics SF-837 A 2 , A 3 and A 4 . , 1971, The Journal of antibiotics.
[16] T. Shomura,et al. Studies on antibiotic SF-837, a new antibiotic. I. The producing microorganism and isolation and characterization of the antibiotic. , 1971, The Journal of antibiotics.
[17] Y. Mikami. Susceptibility patterns of pathogenic Nocardia to some selected antimicrobial agents and their usefulness in the identification work in a clinical laboratory. , 1989 .
[18] J. Everett,et al. An analysis of the 1H and 13C n.m.r. spectra of erythromycin a using two-dimensional methods , 1985 .
[19] H. A. Whaley,et al. MICROBIOLOGICAL TRANSFORMATIONS OF MACROLIDE ANTIBIOTICS. , 1963, Antimicrobial agents and chemotherapy.